These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33236471)

  • 21. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
    Elgaard CDB; Iversen L; Hjuler KF
    J Dermatolog Treat; 2023 Dec; 34(1):2133531. PubMed ID: 36200762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologics switch in psoriasis.
    Wang TS; Tsai TF
    Immunotherapy; 2019 Apr; 11(6):531-541. PubMed ID: 31135243
    [No Abstract]   [Full Text] [Related]  

  • 24. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
    Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
    Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
    Mease PJ
    Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
    Hu Y; Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab.
    Alsenaid A; Piguet V; Lansang P; Miller-Monthrope Y; Yeung J; Joseph M
    J Cutan Med Surg; 2023; 27(3):236-240. PubMed ID: 37014149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.
    Lebwohl M; Menter A; Lain E; Han G; Jacobson A
    J Drugs Dermatol; 2022 Apr; 21(4):354-370. PubMed ID: 35389586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
    Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
    J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
    Molinelli E; Campanati A; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapies in psoriasis: a systematic review.
    Lee EB; Amin M; Bhutani T; Wu JJ
    Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study.
    Kromer C; Wilsmann-Theis D; Gerdes S; Krebs S; Pinter A; Philipp S; Mössner R
    J Dermatolog Treat; 2021 Dec; 32(8):878-882. PubMed ID: 32011917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.
    Ruggiero A; Megna M; Fabbrocini G; Ocampo-Garza SS
    Immunol Res; 2023 Jun; 71(3):328-355. PubMed ID: 36598647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan.
    Saeki H; Ishii K; Joshi A; Bensimon AG; Yang H; Kawaguchi I
    J Dermatolog Treat; 2022 Feb; 33(1):229-239. PubMed ID: 32178555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.